Legal status · United States
Is NNC0480-0389 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. NNC0480-0389 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
NNC0480-0389 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Phase 2 completed in combination with semaglutide. No results published and no approval anywhere. |
| FDA approval status | Investigational. Not approved anywhere. Phase 2 dose finding completed with no published results. |
| Human studies cited | 3 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the NNC0480-0389 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
NNC0480-0389 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What NNC0480-0389 is
A GIP receptor agonist being added to semaglutide in phase 2, with 500 participants. Its mirror image, a GIP antagonist added to semaglutide, is in phase 2 at the same time.
This is the agonist half of the GIP paradox, tested as an add-on rather than as a single molecule. Novo Nordisk makes semaglutide, so pairing it with a separate long-acting GIP receptor agonist is a route to a tirzepatide-like dual mechanism using two drugs instead of one.
Mechanism: A long-acting agonist at the GIP receptor, a class B1 G protein-coupled receptor that raises cyclic AMP. In the pancreatic beta cell that potentiates glucose-stimulated insulin secretion in a glucose-dependent way.
Regulatory history: Investigational. Not approved anywhere. Phase 2 dose finding completed with no published results.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for NNC0480-0389 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
NNC0480-0389 in other countries
Frequently asked questions
Is NNC0480-0389 legal in the United States?
No. NNC0480-0389 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: Phase 2 completed in combination with semaglutide. No results published and no approval anywhere.
Can I buy NNC0480-0389 in the United States?
No approved product exists to buy. In the United States NNC0480-0389 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Phase 2 completed in combination with semaglutide. No results published and no approval anywhere.
Is NNC0480-0389 FDA approved?
No. FDA status: Investigational. Not approved anywhere. Phase 2 dose finding completed with no published results.. Current US classification: "Investigational, not approved". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for NNC0480-0389 live on its compound profile.
NNC0480-0389 profileThis page is general information about the regulatory status of NNC0480-0389 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.